Notice of AGM, Annual Report and Accounts

Final Results for the Year Ended 30 June 2024

Notice of Final Results and Investor Presentation

Further Subscription to raise £1,000,000

Subscription to raise £2,364,000

Patent Allowance in China

US patent allowance

Management Changes

Positive Data from SDC-1801 Phase 1 Clinical Trial

Appointment of Sole Broker

Exercise of Warrants

Final Issue of RiverFort Subscription Shares

Issue of RiverFort Subscription Shares

Issue of RiverFort Subscription Shares

Completion of Equity Fundraise

Result of WRAP Retail Offer

Increase in size of WRAP Retail Offer

Sareum Half-Year Report

WRAP Retail Offer

Equity Fundraise

New Patent Allowance

Notice of Interim Results and Trading Update

Update on SDC-1801 Clinical Trial Progress

Development and commercialisation licence SRA737

Results of AGM

Annual General Meeting Statement

Drawdown of Equity Prepayment Facility

Notice of AGM, Annual Report and Accounts

Initiation of food effects study for SDC-1801

Director Dealings

Sareum enhances SDC-1801 patent protection

Exercise of Share Options and Director Dealings

Final Results for the Year Ended 30 June 2023

Notice of Results and Investor Presentation

Director's Dealing

Director Dealing

Dosing of first subjects in MAD Phase 1a trial

Update on financial and operational progress

Equity Prepayment Facility of up to £5 million

Sareum Announces Two New Granted Patents

Dosing commences in Phase 1a trial of SDC-801

Phase 1a clinical trial for SDC-1801

Approval to initiate Phase 1 clinical trial